09955 CLOUDR
- 3.450
- +0.050+1.47%
CLOUDR News
Zhiyun Health (09955.HK): Loss reduction exceeds expectations, exploring a new P2M model
Zhiyun Health (09955.HK): Release profit forecast Q4 turns loss into profit
Zhiyun Health (09955.HK): Selling subsidiary shares in the form of capital increases to help diversified growth
Zhiyun Health (9955.HK): Proposed share repurchase shows confidence in long-term development
Zhiyun Health (09955.HK): Strategic Cooperation Jinbo Biology lays out collagen circuit
Zhiyun Health (9955.HK): The leading SAAS leader in chronic disease management in China has seen the bright moon
Omo: Maintaining Zhiyun Health (09955) “Keep pace with the market” rating target price reduced to HK$8.6
Zhiyun Health (09955.HK): Digital marketing short-term headwinds and losses have narrowed drastically
CICC: First prize for Zhiyun Health (09955) “Outperform the Industry” rating with a target price of HK$13
Zhiyun Health (09955.HK): Digitalization Empowers Chronic Disease Management Multiple Scenarios to Reshape Patient Journey
Daimo: Maintaining Zhiyun Health's (09955) “Keep pace with the market” rating target price dropped to HK$21
Zhiyun Health (9955.HK) IPO Review: China's largest digital chronic disease management solution provider
Zhiyun Health (9955.HK) IPO Report
IPO Purchase Guide: Zhiyun Health (9955.HK)
Analysis
Price Target
No Data
